Demographic and clinical characteristics for all enrolled participants and participants included in the analyses
| . | All . | Included . |
|---|---|---|
| n = 108 . | n = 98 . | |
| Age, mean (SD) | 12.6 (3.8) | 12.8 (3.7) |
| Sex, n (%) | ||
| Male | 52 (48.1) | 46 (46.9) |
| Female | 56 (51.9) | 52 (53.1) |
| Genotype, n (%) | ||
| HbSS/HbSβ0 thalassemia/HbS-OArab | 78 (72.2) | 72 (73.5) |
| HbSC/HbSβ+ thalassemia | 30 (27.8) | 26 (26.5) |
| Hydroxyurea use, n (%) | ||
| No | 35 (32.4) | 31 (31.6) |
| Yes | 73 (67.6) | 67 (68.4) |
| HCU in prior year∗, median (IQR) | 3 (2,6) | 3 (2,6) |
| HCU for pain in prior year∗, median (IQR) | 2 (1,4.5) | 2 (1,4) |
| Proportion with ≥3 episodes of HCU for pain in prior year∗, n (%) | 51 (47.7) | 45 (46.4) |
| Highest pain score at presentation, median (IQR) | 9.00 (8,10) | 9.00 (8,10) |
| Prescribed medications, n (%) | ||
| Oral opioids (hydrocodone, oxycodone, hydromorphone, morphine, or tramadol)† | 105 (97.2) | 95 (96.9) |
| Nonsteroidal Anti-inflammatory (ibuprofen, naproxen or meloxicam) | 101 (93.5) | 93 (94.9) |
| Adjunctive analgesics including muscle relaxants (clonidine, gabapentin, amitriptyline, lidocaine, cyclobenzaprine, or methocarbamol) | 30 (27.8) | 24 (24.5) |
| Methadone | 1 (0.9) | 1 (1) |
| Laboratory values at enrollment, mean (SD) | ||
| WBC (X 10-9/L) | 12.3 (5.1) | 12.3 (5.1) |
| Hemoglobin (g/dL) | 9.3 (1.7) | 9.3 (1.7) |
| Mean corpuscular volume (fL) | 86.8 (12.6) | 86.9 (12.5) |
| Platelets (X 10-9/L) | 367.9 (166.7) | 363.9 (163.4) |
| . | All . | Included . |
|---|---|---|
| n = 108 . | n = 98 . | |
| Age, mean (SD) | 12.6 (3.8) | 12.8 (3.7) |
| Sex, n (%) | ||
| Male | 52 (48.1) | 46 (46.9) |
| Female | 56 (51.9) | 52 (53.1) |
| Genotype, n (%) | ||
| HbSS/HbSβ0 thalassemia/HbS-OArab | 78 (72.2) | 72 (73.5) |
| HbSC/HbSβ+ thalassemia | 30 (27.8) | 26 (26.5) |
| Hydroxyurea use, n (%) | ||
| No | 35 (32.4) | 31 (31.6) |
| Yes | 73 (67.6) | 67 (68.4) |
| HCU in prior year∗, median (IQR) | 3 (2,6) | 3 (2,6) |
| HCU for pain in prior year∗, median (IQR) | 2 (1,4.5) | 2 (1,4) |
| Proportion with ≥3 episodes of HCU for pain in prior year∗, n (%) | 51 (47.7) | 45 (46.4) |
| Highest pain score at presentation, median (IQR) | 9.00 (8,10) | 9.00 (8,10) |
| Prescribed medications, n (%) | ||
| Oral opioids (hydrocodone, oxycodone, hydromorphone, morphine, or tramadol)† | 105 (97.2) | 95 (96.9) |
| Nonsteroidal Anti-inflammatory (ibuprofen, naproxen or meloxicam) | 101 (93.5) | 93 (94.9) |
| Adjunctive analgesics including muscle relaxants (clonidine, gabapentin, amitriptyline, lidocaine, cyclobenzaprine, or methocarbamol) | 30 (27.8) | 24 (24.5) |
| Methadone | 1 (0.9) | 1 (1) |
| Laboratory values at enrollment, mean (SD) | ||
| WBC (X 10-9/L) | 12.3 (5.1) | 12.3 (5.1) |
| Hemoglobin (g/dL) | 9.3 (1.7) | 9.3 (1.7) |
| Mean corpuscular volume (fL) | 86.8 (12.6) | 86.9 (12.5) |
| Platelets (X 10-9/L) | 367.9 (166.7) | 363.9 (163.4) |
No statistically significant differences between included participants (at least one PROMIS score, n = 98) and excluded (no PROMIS score, n = 10), except for excluded participants having a higher proportion of prescription of adjunctive analgesics (P = .026).
Among those included, those prescribed hydroxyurea were more likely to have HbSS/HbSβ0 thalassemia/HbS-OArab genotype (P <.001), lower hemoglobin (P < .001), higher mean corpuscular volume (P < .001), higher platelet count (P = .039), and higher HCU for pain in the prior year (P = .031).
IQR, interquartile range; WBC, white blood cells.
n=107 (entire cohort) and 97 (included) respectively.
Includes combination medications.